Source: European Parliament
Question for written answer E-001139/2025
to the Commission
Rule 144
Jordan Bardella (PfE)
The global health crisis of 2020 and, more recently, the buyout of a Sanofi division by a US group have brought into relief Europe’s growing dependence on third countries for medicine production, highlighting the risks to the security of supply and public health. This weakness makes Europe vulnerable to stock shortages and price increases, and hampers its responsiveness to crises.
In order to bolster the strategic independence of both France and the rest of Europe, pharmaceutical production needs to be reshored. Indeed, many are calling the sector to be reindustrialised for the sake of reliable and controlled supply.
Against this background, does the Commission intend to set a local production quota as a prerequisite for obtaining a marketing authorisation from the European Medicines Agency?
Submitted: 18.3.2025